- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04756830
A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
This is an open-label uncontrolled study in which all participants will receive two doses of the inactivated adsorbed vaccine against COVID-19, and will be followed up for safety and immunogenicity analysis for 24 months. This study will assess safety and immunogenicity of the inactivated vaccine adsorbed against COVID-19 (CoronaVac) in a population of healthy individuals older than 18 years of age.
The estimated number of participants is 1200. Participants will be recruited within 3-4 months. The total duration of the study is estimated to be 30 months after recruitment begins.
The participants will remain in the study for approximately 24 months. The study will be carried out at the clinical research center of the D'Or Institute for Research and Education (IDOR) located at the Hospital Glória D'Or, in the city of Rio de Janeiro, RJ, Brazil
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 4
Контакты и местонахождение
Места учебы
-
-
-
Rio De Janeiro, Бразилия, 22211-230
- Hospital Gloria D'Or - Hospitais Integrados da Gavea S/A
-
Rio De Janeiro, Бразилия, 22281100
- D'Or Institute for Research and Education
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Adults 18 years of age or older;
- Agree with study procedures after reading and signing the Informed Consent Form
Exclusion Criteria:
- Pregnancy (confirmed by positive β-hCG test), breastfeeding and / or expressing intention to have sexual practices with reproductive potential without using contraceptive methods in the three months following vaccination
- Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease, according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- Diseases with impaired immune system including: neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not controlled according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- Behavioral, cognitive or psychiatric illness that, in the opinion of the principal investigator or his medical representative, affects the participant's ability to understand and collaborate with the requirements of the study protocol
- Any alcohol or drug abuse in the last 12 months prior to inclusion in the study that has caused medical, professional or family problems, as indicated by clinical history;
- History of severe allergic reaction or anaphylaxis to the vaccine or components of the study vaccine;
- History of asplenia;
- Participation in another clinical trial with product administration under investigation during the six months prior to its inclusion in the study or scheduled participation in another clinical trial in the two years following inclusion;
- Previous participation in a COVID-19 vaccine evaluation study or previous exposure to a COVID-19 vaccine;
- Use of immunosuppressive therapies six months prior to inclusion in the study or its scheduled use within two years of inclusion. Immunosuppressive therapies will be considered: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, among others.
- Have received an immunosuppressive dose of corticosteroids in the last three months prior to inclusion in the study or scheduled administration of an immunosuppressive dose of corticosteroids for the three months following inclusion in the study. The dose of corticosteroids considered immunosuppressive is equivalent to prednisone at a dose of 20 mg / day for adults, for more than a week. The continuous use of topical or nasal corticosteroids is not considered immunosuppressive;
- Have received blood products (transfusions or immunoglobulins) in the last three months before inclusion in the study, or scheduled administration of blood products or immunoglobulin in the two years following inclusion in the study;
- Suspected or confirmed fever within 72 hours prior to vaccination or axillary temperature greater than 37.8 ° C * on the day of vaccination (inclusion may be postponed until the participant completes 72 hours without fever);
- Possible or confirmed case of COVID-19 on the day of vaccination (vaccination can be postponed until the participant completes 72 hours without symptoms or the diagnosis is ruled out);
- Have received vaccine with live attenuated virus in the last 28 days or inactivated vaccine in the last 14 days prior to their inclusion in the study, or have immunization scheduled for the first 28 days after their inclusion in the study;
- History of bleeding disorders (for example, deficiency of clotting factors, coagulopathy, platelet dysfunction), or previous history of bleeding or significant bruising after IM injection or venipuncture.
- Any other condition that, in the opinion of the principal investigator or his medical representative, could jeopardize the safety or rights of a potential participant or that would prevent him from complying with this protocol.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Профилактика
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Другой: Vaccination
All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
|
Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Frequency of local and systemic adverse reactions in the first 7 days after immunization
Временное ограничение: Seven days after each immunization
|
Frequency of solicited and unsolicited local and systemic adverse reactions in the first 7 days after vaccination per age group (18-59 years old and 60 years old or older), attributed to the vaccine after causality assessment
|
Seven days after each immunization
|
Seroconversion rates
Временное ограничение: Two weeks after the second immunization
|
Seroconversion rates in the second week after the second dose of the vaccine per age group (18-59 years and 60 years old or older).
|
Two weeks after the second immunization
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Frequency of adverse reactions up to 28 days after immunization
Временное ограничение: 28 days after the second immunization
|
Frequency of unsolicited local and systemic adverse reactions up to 28 days after the second dose of the vaccine per age group (18-59 years old and 60 years old or older), attributed to the vaccine after causality assessment
|
28 days after the second immunization
|
Frequency of severe adverse events
Временное ограничение: Up to 12 months after first immunization
|
Frequency of severe adverse events after vaccination, attributed to the vaccine after causality assessment
|
Up to 12 months after first immunization
|
Frequency of adverse events of special interest
Временное ограничение: Up to 12 months after first immunization
|
Frequency of adverse events of special interest after receiving, at least, one dose of the vaccine
|
Up to 12 months after first immunization
|
Cell-mediated immune response
Временное ограничение: At inclusion and 4 weeks after the second vaccination
|
Cell-mediated immune response at inclusion and four weeks after the second vaccination per age group (18-59 years old and 60 years old or older).
|
At inclusion and 4 weeks after the second vaccination
|
Frequency of detection of antibodies against SARS-CoV-2
Временное ограничение: At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Frequency of detection of antibodies against SARS-CoV-2 at inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second dose of the vaccine against COVID-19.
|
At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Geometric mean titer of neutralizing antibodies
Временное ограничение: At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Geometric mean titer of neutralizing antibodies against SARS-CoV-2 at inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second dose of the vaccine against COVID-19.
|
At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Frequency of confirmed cases of COVID-19
Временное ограничение: Up to 24 months after inclusion
|
Frequency of confirmed cases of COVID-19 per age group (18-59 years old and 60 years old or older) over 24 months.
|
Up to 24 months after inclusion
|
Frequency of SARS-CoV-2 variants of concern (VOC)
Временное ограничение: Up to 24 months after inclusion
|
Frequency of SARS-CoV-2 variants of concern (VOC) in confirmed cases of COVID-19.
|
Up to 24 months after inclusion
|
Humoral and cellular immune response
Временное ограничение: Up to 24 months after inclusion
|
Humoral and cellular immune response in confirmed cases of COVID-19
|
Up to 24 months after inclusion
|
Соавторы и исследователи
Соавторы
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- IDOR_VAC_01
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования COVID-19
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera Niguarda... и другие соавторыЗавершенный
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustЗавершенныйCOVID-19Соединенное Королевство
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...ЗавершенныйПост-острые последствия COVID-19 | Состояние после COVID-19 | Долго-COVID | Хронический синдром COVID-19Италия
-
Indonesia UniversityРекрутингПост-COVID-19 синдром | Долгий COVID | Состояние после COVID-19 | Пост-COVID-синдром | Длинный COVID-19Индонезия
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkЕще не набираютПост-COVID-19 синдром | Долгий COVID | Длинный Covid19 | Состояние после COVID-19 | Пост-COVID-синдром | Состояние после COVID-19, неуточненное | Пост-COVID-состояниеНидерланды
-
Yang I. PachankisАктивный, не рекрутирующийРеспираторная инфекция COVID-19 | Стрессовый синдром COVID-19 | Побочная реакция вакцины против COVID-19 | COVID-19-ассоциированная тромбоэмболия | Пост-интенсивный синдром COVID-19 | Инсульт, связанный с COVID-19Китай
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaРекрутингCOVID-19 пандемия | COVID-19 прививки | Вирусное заболевание COVID-19Индонезия
-
Endourage, LLCРекрутингДолгий COVID | Длинный Covid19 | Пост-острый COVID-19 | Долгосрочный COVID | Долгосрочный COVID-19 | Пост-острый синдром COVID-19Соединенные Штаты
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... и другие соавторыРекрутингCOVID-19 | Пост-COVID-19 синдром | Пост-острый COVID-19 | Острый COVID-19Китай
Клинические исследования Adsorbed COVID-19 (inactivated) Vaccine
-
Karamanoğlu Mehmetbey UniversityРекрутинг
-
AstraZenecaЗавершенныйCOVID-19Соединенное Королевство
-
Hasanuddin UniversityChulalongkorn UniversityЗавершенный
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaРекрутингCOVID-19 пандемия | COVID-19 прививкиИндонезия
-
University of PennsylvaniaPublic Health Management CorporationЗавершенныйCOVID-19Соединенные Штаты
-
AstraZenecaЗавершенныйCOVID-19Соединенное Королевство
-
Melike CengizЗавершенный
-
University of PennsylvaniaPublic Health Management CorporationЗавершенный
-
University of Texas at AustinНеизвестныйОтсутствие продовольственной безопасностиСоединенные Штаты
-
University of AberdeenЕще не набираютCOVID-19 | Легочная эмболия